Unhappy with vaccine test results in elderly patients, drugmakers GlaxoSmithKline and Sanofi said Friday that their potential COVID-19 vaccine won’t be ready until late next year.
Read More
President Donald Trump made a quick visit to the Triangle on Monday to tout his administration’s efforts to produce a vaccine for coronavirus.
Read More
The investigational vaccine was developed by the biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial is to be conducted at nearly 100 US research sites, according to Moderna.
Read More
An ancient relative of tobacco is at the heart of a new COVID-19 vaccine under development by Medicago and GSK. Here’s a look at what’s happening.
Read More
Scientists from the National Institute of Allergy and Infectious Diseases are infecting willing subjects with influenza A (the infamous H1N1 virus, which has caused pandemics) and closely monitoring their symptoms to better understand how the virus works and how to control it. One site included in the program is Duke University.
Read More
Drug giant GlaxoSmithKline is selling two travel vaccines in acquired from Novartis in 2015 in a deal worth more than $1 billion.
Read More
GlaxoSmithKline will expand the production capacity at its Hamilton, Montana, facility, where it produces components used in several of vaccines, including ones to help prevent malaria and shingles.
Read More
In the quest to develop an effective HIV vaccine, researchers have focused attention on identifying and targeting the region of the virus’s outer envelope where a lineage of antibodies are able to dock and neutralize the virus. That focus may change due to research at Duke University.
Read More
Four researchers at UNC-Chapel Hill’s School of Medicine filed an application with the U.S. Patent and Trademark Office for a new Zika virus vaccine.
Read More
